Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John J McGuire

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Current Pharmaceutical Design|October 8, 2003
Anticancer antifolates: current status and future directionsJohn J McGuire
Current Pharmaceutical Design|August 24, 2004
Proteinase-activated Receptor 2 (PAR2): a challenging new target for treatment of vascular diseasesJohn J McGuire
Stroke|March 24, 2007
Effects of poststroke losartan versus captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRspJohn S Smeda, John J McGuire
Biochemical Pharmacology|January 29, 2009
Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogsJohn J McGuire, William H Haile
Vitamins and Hormones|September 23, 2008
Mechanism-based inhibitors of folylpoly-gamma-glutamate synthetase and gamma-glutamyl hydrolase: control of folylpoly-gamma-glutamate homeostasis as a drug targetJames K Coward, John J McGuire
Biochimica Et Biophysica Acta|September 20, 2005
Submitochondrial localization of the mitochondrial isoform of folylpolyglutamate synthetase in CCRF-CEM human T-lymphoblastic leukemia cellsJayakumar R Nair, John J McGuire
Plos One|February 15, 2013
Attenuated vasodilator effectiveness of protease-activated receptor 2 agonist in heterozygous par2 knockout miceJohn C Hennessey, John J McGuire
British Journal of Pharmacology|March 24, 2011
Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic miceSatomi Kagota, Elizabeth Chia, John J McGuire
Biological & Pharmaceutical Bulletin|December 5, 2017
Progression of Time-Dependent Changes to the Mechanisms of Vasodilation by Protease-Activated Receptor 2 in Metabolic SyndromeKana Maruyama, John J McGuire, Satomi Kagota
Biomed Research International|March 24, 2016
Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic ReviewSatomi Kagota, Kana Maruyama, John J McGuire
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Current Pharmaceutical Design|October 8, 2003
Anticancer antifolates: current status and future directionsJohn J McGuire
Current Pharmaceutical Design|August 24, 2004
Proteinase-activated Receptor 2 (PAR2): a challenging new target for treatment of vascular diseasesJohn J McGuire
Stroke|March 24, 2007
Effects of poststroke losartan versus captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRspJohn S Smeda, John J McGuire
Biochemical Pharmacology|January 29, 2009
Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogsJohn J McGuire, William H Haile
Vitamins and Hormones|September 23, 2008
Mechanism-based inhibitors of folylpoly-gamma-glutamate synthetase and gamma-glutamyl hydrolase: control of folylpoly-gamma-glutamate homeostasis as a drug targetJames K Coward, John J McGuire
Biochimica Et Biophysica Acta|September 20, 2005
Submitochondrial localization of the mitochondrial isoform of folylpolyglutamate synthetase in CCRF-CEM human T-lymphoblastic leukemia cellsJayakumar R Nair, John J McGuire
Plos One|February 15, 2013
Attenuated vasodilator effectiveness of protease-activated receptor 2 agonist in heterozygous par2 knockout miceJohn C Hennessey, John J McGuire
British Journal of Pharmacology|March 24, 2011
Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic miceSatomi Kagota, Elizabeth Chia, John J McGuire
Biological & Pharmaceutical Bulletin|December 5, 2017
Progression of Time-Dependent Changes to the Mechanisms of Vasodilation by Protease-Activated Receptor 2 in Metabolic SyndromeKana Maruyama, John J McGuire, Satomi Kagota
Biomed Research International|March 24, 2016
Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic ReviewSatomi Kagota, Kana Maruyama, John J McGuire
Pageof 7